Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Aerovate Therapeutics, Inc. AVTE NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$13.00
+385.1%

Aerovate Therapeutics, Inc. (AVTE) is a Biotechnology company in the Healthcare sector, currently trading at $2.68. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is AVTE = $13 (+385.1% upside).

Net income is $127M (loss), growing at -40.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $724,000 against $333M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 21.09 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $350M.

Analyst outlook: 2 / 8 analysts rate AVTE as buy (25%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$13.00
▲ 385.07% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Aerovate Therapeutics, Inc., the average price target is $13.00, with a high forecast of $35.00, and a low forecast of $2.00.
Highest Price Target
$35.00
Average Price Target
$13.00
Lowest Price Target
$2.00

AVTE SharesGrow Score Overview

59/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AVTE

✓
VALUE Pass
100/100
AVTE trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $13, implying +385.1% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
AVTE: +0%/yr revenue is, -40.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet AVTE: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 21.09 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
AVTE: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 2 / 8 analysts rate AVTE as buy (25%). Analyst consensus target is $13 (+385.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.6296-884.975
Volume981.8K
Avg Volume (30D)7.99K
Market Cap$77.68M
Beta (1Y)0.95
Share Statistics
EPS (TTM)-3,193.30
Shares Outstanding$31.36M
IPO Date2021-06-30
Employees4
CEOTimothy P. Noyes
Financial Highlights & Ratios
EBITDA$-113.54M
Net Income$-127.41M
Operating Income$-113.54M
Total Cash$88.44M
Total Debt$724K
Net Debt$-87.71M
Total Assets$349.78M
Price / Earnings (P/E)-0
Analyst Forecast
1Y Price Target$2.00
Target High$35.00
Target Low$2.00
Upside-25.4%
Rating ConsensusHold
Analysts Covering8
Buy 25% Hold 75% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS0080641071

Price Chart

Track all markets on TradingView
AVTE
Aerovate Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
2.63 52WK RANGE 884.98

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 ADAG
ADAG
Adagene Inc.
$3.81
-0.78%
 ANTX
ANTX
AN2 Therapeutics, Inc.
$2.98
-1.00%
 ACRV
ACRV
Acrivon Therapeutics, Inc. Common Stock
$1.64
+1.86%
 ANEB
ANEB
Anebulo Pharmaceuticals, Inc.
$0.50
-0.04%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message